AHFS drug information
著者
書誌事項
AHFS drug information
American Society of Health-System Pharmacists, c2022
- 2022
- タイトル別名
-
American Hospital Formulary Service drug information
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes index
内容説明・目次
内容説明
AHFS Drug Information (R) 2022 contains the most dependable drug information available-all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.
With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.
Updates in the new edition:
The latest information on COVID-19 vaccines and COVID-19 monoclonal antibodies available under FDA Emergency Use Authorizations (EUAs), including clinical considerations from the US Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH).
Information on patient selection and appropriate use of corticosteroids in the management of COVID-19 based on recent guidelines from NIH and the World Health Organization (WHO).
Contemporary issues such as anticoagulant reversal strategies and use of direct oral anticoagulants versus warfarin for treatment of venous thromboembolism or atrial fibrillation.
Current best practices such as reversal of neuromuscular blocking agents for prevention of postoperative residual neuromuscular blockade.
Newly published information on breakthrough oncology drugs approved as part of the FDA's accelerated approval program.
Expanded content on off-label uses, real-world data, and long-term clinical data.
Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Addition of 51 new molecular entities (NMEs) or new therapeutic biological products approved since January 2021.
「Nielsen BookData」 より